Swedish Orphan Biovitrum (BIOVF)
(Delayed Data from OTC)
$25.76 USD
+2.89 (12.62%)
Updated May 3, 2024 09:52 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIOVF 25.76 +2.89(12.62%)
Will BIOVF be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BIOVF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIOVF
All You Need to Know About Swedish Orphan Biovitrum (BIOVF) Rating Upgrade to Strong Buy
Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss Estimates
BIOVF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock?
Is Swedish Orphan Biovitrum (BIOVF) Stock Undervalued Right Now?
Swedish Orphan Biovitrum (BIOVF) Beats Q2 Earnings and Revenue Estimates
Other News for BIOVF
Swedish Orphan Biovitrum assumed with a Buy at Jefferies
Apellis, Sobi present one-year data from Phase 2 study of pegcetacoplan
SEB Equities gets more bearish on Swedish Orphan Biovitrum, downgrades shares
Swedish Orphan Biovitrum AB reports Q1 results
Swedish Orphan Biovitrum AB (publ) 2024 Q1 - Results - Earnings Call Presentation